Resiquimod
- Generic Name
- Resiquimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H22N4O2
- CAS Number
- 144875-48-9
- Unique Ingredient Identifier
- V3DMU7PVXF
- Background
A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodu...
- Indication
Investigated for use/treatment in genital herpes.
- Associated Conditions
- -
- Associated Therapies
- -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT01748747
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 59
- Registration Number
- NCT01737580
- Locations
- ๐จ๐ฆ
University of British Columbia Vancouver General Hospital, Vancouver, British Columbia, Canada
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00470379
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Study With a Topical Gel to Treat Common Warts in Adults
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT00117923
- Locations
- ๐บ๐ธ
Oregon Medical Research Center, Portland, Oregon, United States
Study With a Topical Gel to Treat Common Warts in Adults
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00117871
- Locations
- ๐บ๐ธ
Minnesota Clinical Study Center, Fridley, Minnesota, United States
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
- Conditions
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT00116662
- Locations
- ๐บ๐ธ
Vermont, Burlington, Vermont, United States
๐บ๐ธUtah, Layton, Utah, United States
๐บ๐ธMassachusetts, Boston, Massachusetts, United States
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
- Conditions
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT00116675
- Locations
- ๐บ๐ธ
Longmont Clinic/Longmont Medical Research Network, Longmont, Colorado, United States
๐บ๐ธMercy Health Research, St. Louis, Missouri, United States
๐บ๐ธWalla Walla Clinic, Walla Walla, Washington, United States
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
- Conditions
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT00115141
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
- Conditions
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT00114920
- Locations
- ๐บ๐ธ
Welborn Clinic, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.